Pancreatic cancer is the 11th most common cancer in the USA and the fourth most common cause of death from cancer. During their lifetime, a person’s average risk of developing pancreatic cancer is one in 67. Pancreatic cancer accounts for approximately 3% of all cases of cancer in the USA, and 7% of cancer deaths are due to pancreatic cancer.
The main treatments for pancreatic cancer include:
- Radiation therapy
- Chemotherapy (and other drugs)
These treatments can also be combined in some patients.
AstraZeneca is committed to pancreatic cancer research to help find effective treatments for this disease. We have recently started a new pancreatic cancer study (also known as clinical trial involving people around the world with a specific type of pancreatic cancer known as ”BRCA-mutated”, that is metastatic (i.e. has spread outside of the pancreas). This study is called POLO, and will include people who have been diagnosed and are receiving initial chemotherapy for metastatic pancreatic cancer, whose disease is now stabilized or improved.
The goal of the POLO study is to determine if a potential new medicine (otherwise known as an ‘investigational therapy’) called olaparib could be a successful therapy for this type of metastatic pancreatic cancer, to help control the disease between chemotherapy treatments. This website provides information about the POLO study for patients with metastatic pancreatic cancer who may be interested in being a volunteer for a clinical trial. There is also information for caregivers and relatives of patients with pancreatic cancer, as well as for healthcare professionals.